JERUSALEM — Teva Pharmaceutical Industries Ltd. has rolled out niacin extended-release tablets in dosages of 500 mg, 750 mg and 1000 mg in the United States.
Teva said Friday that its product is the generic equivalent of AbbVie Inc.’s Niaspan extended-release niacin tablets.
Niaspan is indicated to be used, along with diet, to lower elevated TC, LDL-C, Apo B and TG levels and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia.
Teva noted that it was the first to file for the generic version of Niaspan, making its product eligible for 180 days of marketing exclusivity.
Niaspan had annual sales of about $1.12 billion as of June 30 in the United States, according to IMS Health data reported by Teva.
